AI Analysis
AI-generated analysis. Always verify with the original filing.
Can-Fite BioPharma Ltd. announced the publication of a peer-reviewed study in the International Journal of Obesity demonstrating namodenoson's anti-obesity effect in vitro and in a high-fat diet murine model, with significant inhibition of adipocyte proliferation, lipid accumulation, and weight gain. The findings support namodenoson's potential in obesity alongside its ongoing Phase III for liver cancer and Phase IIb for MASH.
Key Takeaways
1Publication in International Journal of Obesity on namodenoson's anti-obesity effects
2Namodenoson inhibited adipocyte proliferation and lipid droplet accumulation dose-dependently in 3T3-L1 cells
3Daily oral namodenoson for 4 weeks reduced weight gain vs placebo in high-fat diet murine model
4Upregulated adiponectin and suppressed PI3K, NF-κB, Akt, Wnt/β-catenin pathways
5Namodenoson in Phase III for advanced liver cancer, Phase IIb for MASH enrolling patients, Phase IIa for pancreatic cancer
6Consistent with prior Phase IIa MASH study showing reductions in liver fat and body weight